» Articles » PMID: 30582447

The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction

Overview
Journal Circ Res
Date 2018 Dec 25
PMID 30582447
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction (HFpEF). Interventions that enhance pulmonary vasodilation might be beneficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion. Intravenous β-agonists reduce pulmonary vascular resistance but are not suitable for chronic use.

Objective: We hypothesized that the inhaled β-adrenergic agonist albuterol would improve pulmonary vasodilation during exercise in patients with HFpEF, without increasing left heart filling pressures.

Methods And Results: We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjects with HFpEF using high-fidelity micromanometer catheters and expired gas analysis. The primary end point was pulmonary vascular resistance during exercise. Subjects with HFpEF (n=30) underwent resting and exercise hemodynamic assessment and were then randomized 1:1 to inhaled, nebulized albuterol or placebo. Rest and exercise hemodynamic testing was then repeated. Albuterol improved the primary end point of exercise pulmonary vascular resistance as compared with placebo (-0.6±0.5 versus +0.1±0.7 WU; P=0.003). Albuterol enhanced cardiac output reserve and right ventricular pulmonary artery coupling, reduced right atrial and pulmonary artery pressures, improved pulmonary artery compliance, and enhanced left ventricular transmural distending pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures.

Conclusions: Albuterol improves pulmonary vascular reserve in patients with HFpEF without worsening left heart congestion. Further study is warranted to evaluate the chronic efficacy of β-agonists in HFpEF and other forms of pulmonary hypertension.

Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02885636.

Citing Articles

Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.

Shah S, Bonderman D, Borlaug B, Cleland J, Lack G, Lu W Circ Heart Fail. 2025; :e011381.

PMID: 40066571 PMC: 11905905. DOI: 10.1161/CIRCHEARTFAILURE.123.011381.


Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension.

Reddy Y, Frantz R, Hassoun P, Hemnes A, Horn E, Leopold J J Am Coll Cardiol. 2024; 84(22):2196-2210.

PMID: 39453363 PMC: 11760158. DOI: 10.1016/j.jacc.2024.08.061.


Autonomic control of the pulmonary circulation: Implications for pulmonary hypertension.

Plunkett M, Paton J, Fisher J Exp Physiol. 2024; 110(1):42-57.

PMID: 39453284 PMC: 11689128. DOI: 10.1113/EP092249.


Allergic asthma is a risk factor for human cardiovascular diseases.

Guo J, Zhang Y, Liu T, Levy B, Libby P, Shi G Nat Cardiovasc Res. 2024; 1(5):417-430.

PMID: 39195946 DOI: 10.1038/s44161-022-00067-z.


Percent Predicted Peak Exercise Oxygen Pulse Provides Insights Into Ventricular-Vascular Response and Prognosticates HFpEF.

Li J, Slocum C, Sbarbaro J, Schoenike M, Campain J, Prasad C JACC Adv. 2024; 3(8):101101.

PMID: 39105119 PMC: 11299572. DOI: 10.1016/j.jacadv.2024.101101.


References
1.
Reddy Y, Olson T, Obokata M, Melenovsky V, Borlaug B . Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2018; 6(8):665-675. PMC: 6076329. DOI: 10.1016/j.jchf.2018.03.003. View

2.
Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

3.
Andersen M, Hwang S, Kane G, Melenovsky V, Olson T, Fetterly K . Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail. 2015; 8(3):542-50. DOI: 10.1161/CIRCHEARTFAILURE.114.002114. View

4.
Lewis G, Bossone E, Naeije R, Grunig E, Saggar R, Lancellotti P . Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases. Circulation. 2013; 128(13):1470-9. DOI: 10.1161/CIRCULATIONAHA.112.000667. View

5.
Simon M, Vanderpool R, Nouraie M, Bachman T, White P, Sugahara M . Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction. JCI Insight. 2016; 1(18):e89620. PMC: 5085611. DOI: 10.1172/jci.insight.89620. View